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Abstract
Background: Both methadone- and buprenorphine-treated opioid-dependent patients frequently
show cognitive deficits in attention, working memory, and verbal memory. However, no study has
compared these patient groups with each other during early opioid substitution treatment (OST).
Therefore, we investigated attention, working memory, and verbal memory of opioid-dependent
patients within six weeks after the introduction of OST in a naturalistic setting and compared to
those of healthy controls.
Methods: The sample included 16 methadone-, 17 buprenorphine/naloxone-treated patients, and
17 healthy controls matched for sex and age. In both groups buprenorphine was the main opioid
of abuse during the recent month. Benzodiazepine codependence, recent use, and comedication
were also common in both patient groups. Analysis of variance was used to study the overall group
effect in each cognitive test. Pair-wise group comparisons were made, when appropriate
Results: Methadone-treated patients, as a group, had significantly slower simple reaction time (RT)
compared to buprenorphine/naloxone-treated patients. In Go/NoGo RT methadone patients were
significantly slower than controls. Both patient groups were significantly debilitated compared to
controls in working memory and verbal list learning. Only methadone patients were inferior to
controls in story recall. In simple RT and delayed story recall buprenorphine/naloxone patients with
current benzodiazepine medication (n = 13) were superior to methadone patients with current
benzodiazepine medication (n = 13). When methadone patients were divided into two groups
according to their mean dose, the patient group with a low dose (mean 40 mg, n = 8) showed
significantly faster simple RT than the high dose group (mean 67 mg, n = 8).
Conclusion: Deficits in attention may only be present in methadone-treated early phase OST
patients and may be dose-dependent. Working memory deficit is common in both patient groups.
Verbal memory deficit may be more pronounced in methadone-treated patients than in
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buprenorphine/naloxone-treated patients. In sum, to preserve cognitive function in early OST, the
use of buprenorphine/naloxone may be more preferable to methadone use of, at least if
buprenorphine has been recently abused and when benzodiazepine comedication is used.
Longitudinal studies are needed to investigate if the better performance of buprenorphine/
naloxone-treated patients is a relatively permanent effect or reflects "only" transient opioid
switching effect.
Background
In opioid substitution treatment, the opioid-dependent
patient receives long-acting mu opioid receptor agonists
in order to prevent withdrawal symptoms and to reduce
craving for street opioids. The full mu opioid agonist
methadone is the most commonly used drug in OST pro-
grams. If overdosed, which may happen in cases of abuse,
methadone may cause fatal respiratory depression. There-
fore, partial mu opioid receptor agonist and kappa recep-
tor antagonist buprenorphine, with a ceiling effect on
respiratory depression, has been increasingly used in OST
programs. Buprenorphine, however, is commonly abused
in several countries; and in combination with other psy-
choactive substances it may also be hazardous [1,2].
Therefore, a safer drug combining buprenorphine and
naloxone has been developed. The compound contains
buprenorphine and naloxone in 4:1 ratio, and if used sub-
lingually, it has practically equal pharmacokinetic proper-
ties as buprenorphine alone [3,4].
Already during the first few weeks of their OST patients
often show reduction of use of illegal opioids and related
problem behaviors [5,6]. Some patients, however, experi-
ence negative treatment effects including cognitive distur-
bances and relate them to their OST drug. This needs to
taken seriously as drug-dependent patients experiencing
troubles in concentrating and remembering have poor
treatment engagement and treatment prognosis [7,8].
Thus, it is relevant to study objective cognitive function of
early OST patients.
When given to healthy volunteers, both methadone and
buprenorphine have shown adverse effects on attention
and memory [9,10]. When these drugs are given to opi-
oid-dependent patients, their cognitive effects may be dif-
ferent because these patients have tolerance for opioids.
As an example of this, a single dose of methadone (5 or 10
mg) slowed down simple RT of healthy volunteers but
had no such an effect on methadone-treated opioid-
dependent patients in stabilized treatment (a stable meth-
adone dose regimen from 20 mg to 70 mg for at least one
month) [11]. In the same vein, a one third increase in
methadone did not affect memory or RT performance of
opioid-dependent patients who had been in treatment at
least for 6 months [12]. However, switching from opioid
of abuse to different opioid for OST purposes may cause
transient cognitive side-effects. In accordance with this
idea heroin abusing opioid-dependent patients studied
during the first week of methadone-aided withdrawal
treatment showed verbal memory deterioration after the
full methadone dose of 35 mg on average compared to
placebo or to halved dose [13].
Cognitive effects of buprenorphine in OST patients are
not well known. Some evidence exists for buprenorphine
having less adverse effect on driving-related attention than
methadone [3,4,14,15]. However, in a recent comparison,
made after 12 months of OST, both buprenorphine and
methadone-treated patients were inferior to controls in
visual memory [16].
In clinical settings, OST patients typically have used, and
may still use, other substances of abuse. Benzodiazepine
abuse is particularly common among individuals starting
OST [17]. At the same time other psychoactive drugs are
often prescribed to them. Yet, few studies have dealt with
this issue. For instance, the studies of Soyka et al., which
showed better performance among buprenorphine-than
among methadone-treated OST patients, mainly describe
patients with current polysubstance abuse and psychoac-
tive polytherapy [14,15].
In sum, both methadone and buprenorphine/naloxone as
such or in combination with other psychoactive medica-
tions may have negative effect on cognition in OST
patients. To our knowledge, no study has addressed this
issue in a naturalistic clinical sample of patients who are
starting their OST – a period when cognitive deficits might
be pronounced. Therefore, we evaluated attention, work-
ing memory, and verbal memory of methadone- or
buprenorphine/naloxone-treated patients starting OST
and compared these to those of controls.
Methods
Participants
The study participants with opioid dependence were vol-
unteers from a consecutive series of patients accepted for
standard OST in the addiction clinics of Helsinki area. The
introduction of combined buprenorphine/naloxone OST
in Helsinki in 2004 enabled a comparison of cognitive
abilities between the methadone-treated and the
buprenorphine/naloxone-treated patients. Healthy con-BMC Clinical Pharmacology 2007, 7:5 http://www.biomedcentral.com/1472-6904/7/5
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trol participants were recruited from adult education cent-
ers and by word of mouth.
The inclusion criteria for all participants were age between
18 – 50 years. The additional inclusion criteria for OST
patients were opioid dependence according to DSM-IV,
and the start of OST during the last six weeks. We excluded
participants with current uncontrolled polysubstance
abuse, acute alcohol abuse, or acute axis I psychiatric mor-
bidity according to Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) other than substance abuse
disorders. Also we excluded participants with severe brain
injury, chronic neurological disease, history of other than
substance-induced psychoses, epileptic seizures, human
immunodeficiency virus (HIV) infection, pregnancy, or
primary cognitive deficit. Each opioid-dependent partici-
pant eligible for our study was screened by urine sample
for substance abuse on the day of testing and at least once
in the preceding week. Healthy controls were selected for
substance abuse screening at random and we screened
one third of them. After excluding participants showing
positive drug screen on the day of testing we included 16
methadone-, 17 buprenorphine/naloxone-treated
patients, and 17 healthy controls.
The study protocol was accepted by the Ethics Committee
of Helsinki University Central Hospital. We obtained a
written informed consent according to the Declaration of
Helsinki from all participants, and paid them € 60 if they
attended all the necessary visits.
Table 1 shows major demographic variables of each
group. When appropriate, we performed pair-wise group
comparisons with analysis of variance (ANOVA) or with
chi-square-test. The groups did not differ in age or sex dis-
tribution. The OST groups did not differ in history of sub-
stance abuse or duration of OST. As shown in Table 1 the
control group had more education than the patient
groups. The control group had superior verbal intelligence
(Verbal IQ) relative to the methadone patients but not to
the buprenorphine/naloxone patients. The main opioid
of abuse within the last month was buprenorphine
among all participants of the buprenorphine/naloxone
group and among most participants (75%) in the metha-
Table 1: Group demographics
Methadone
(n = 16)
Buprenorphine/Naloxone
(n = 17)
Control
(n = 17)
Group comparison
p-values
Age, years (M, SD) 30.8 (8.8) 28.1 (6.3) 31.1 (11.2) ns
Sex: females/males 9/7 7/10 9/8 ns
Verbal intelligence a (M, SD) 98.4 (8.7) 102.4 (8.4) 105.4 (9.8) C > M*
Education, years (M, SD) 10.4 (2.0) 11.1 (2.2) 13,0 (1.7) C > M**
C > BN**
Dependencies
Opioid 100% 100% - nsb
Alcohol 0% 6% nsb
Amphetamine 0% 11% nsb
Benzodiazepines 100% 89% nsb
Cannabis 6% 11% nsb
Main opioid of abuse used within last month (%)
Buprenorphine 75% 100% - nsb
Heroin 13% 0% nsb
Methadone 13% 0% nsb
Other substances of abuse used within last month (%)
Alcohol (heavy use)c 6% 17% 6% ns
Amphetamine 19% 29% 0% ns
Benzodiazepined 94% 94% 0% M & BN > C**
Cannabis 38% 24% 0% M > C*
Nicotine (daily use) 100% 100% 35% M & BN > C**
Duration of opioid substitution treatment in the day of testing, days 
(M, SD)
14.3 (7.4) 11.0 (8.1) - nsb
Duration of opioid abuse, years (M, SD) 12.1 (7.7) 10.0 (3.5) - nsb
Duration of any substance abuse, years (M, SD) 16.9 (8.7) 15.7 (5.0) - nsb
aEstimation based on WAIS-R Vocabulary score.
bTested only between methadone- and buprenorphine/naloxone-treated patients.
cAlcohol use was considered heavy if it was at least mean weekly 16 portions (12 g) for females and 24 weekly portions for males.
dIncludes benzodiazepines used on prescription.
M = methadone, BN = buprenorphine/naloxone
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 
0.05.BMC Clinical Pharmacology 2007, 7:5 http://www.biomedcentral.com/1472-6904/7/5
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done group. There were four cases (25%) of recent month
abuse of heroin or methadone in the methadone-treated
group. Also participants in the buprenorphine/naloxone
group reported, however, earlier periods of heroin or
methadone abuse. As expected, nearly all opioid-depend-
ent participants had used also other substances of abuse
within the last month. In general, these non-selected opi-
oid-dependent participants represent reasonably well cur-
rent opioid abusing populations in Finland where
buprenorphine has become the main street opioid [18].
There has been a similar trend for increase of buprenor-
phine abuse world-wide [2].
Procedure
Cognitive testing was done three to six hours after the
administration of opioid substitution drug, i.e. when drug
plasma concentration is known to be highest [19]. Under
supervision, the methadone patients were given a mean
dose of 53.4 mg (SD = 18.6) of methadone, range 30 –
105 mg, in liquid form on the test day morning. The
buprenorphine/naloxone patients, also under supervi-
sion, received a mean dose of 15.8 mg (SD = 3.2) of
buprenorphine and 3.9 mg (SD = 0.8) of naloxone (range
8 – 24 mg of buprenorphine and 2 – 6 mg of naloxone) as
a sublingual tablet. In this naturalistic study, all partici-
pants received their prescribed psychoactive medications
on the test morning according to their clinical dose regi-
men. After that, however, opioid withdrawal syndrome
relievers were given according to individual needs of the
patients. Medications taken by the patients in the 24 hour
period before the test are described in Table 2. Notably, all
participants in both groups were either dependent on
benzodiazepines, had abused them during last month, or
were given them as a part of their early OST medications.
Table 2: Comedications among OST patients within the last 24 h before testing
Medications used within 24 hours of test Methadone-treated patients
(n = 16)
Buprenorphine/Naloxone- 
treated patients
(n = 17)
Proportion of patients Dose, range Proportion of patients Dose, range
Antidepressives (any) 44 % 35'%
Essitalopram 6% 5 mg
Citalopram 6 % 20 mg
Doxepine 12% 75 – 100 mg
Fluoxetine 13% 20 – 30 mg
Mirtazapine 13% 15 mg
Paroxetine 6% 50 mg
Sertraline 6% 50 mg 12% 50 mg
Venlaflaxine 12% 75 mg
Anxiolytics, sedatives and hypnotics:
Benzodiazepines (any) 81 % 76%
Diazepam 38% 5–20 mg 29% 15 -40 mg
Oxazepam 44% 45 – 120 mg 47% 30 – 90 mg
Nitratzepam* 6% 20 mg
Tematzepam * 19% 20 mg 12% 20 mg
Non-benzodiazepine hypnotics (any) 25% 35%
Zolpidem * 6% 10 mg 6% 15 mg
Zopiclone * 19% 7.5 – 15 mg 24% 7.5 – 15 mg
Neuroleptics † (any) 25% 18%
Chlorpromazine 6% 50 mg
Flupenthixole 6% 0.5 mg
Levomepromazine 6% 150 mg 6% 100 mg
Quetiapine 13% 50–100 mg 6% 300 mg
Opioid withdrawal symptom or pain relievers (any) 69 % 53%
Hydroxyzine 38% 25–200 mg 24% 75 – 300 mg
Ibuprofeine 13% 600– 2400 mg 6% 400 mg
Lofexidine 6% 0.2mg 18% 0.2 – 0.6 mg
Metoclopramide 6% 10 mg
Naproxen 6% 500 mg 6% 500 mg
Propranol 6% 20 mg
Valproate 13% 500 – 1000 mg 24% 500 – 1000 mg
None medication 13% 12%
* Used as a hypnotic the night before testing.
† Used with anxiolytic indicationsBMC Clinical Pharmacology 2007, 7:5 http://www.biomedcentral.com/1472-6904/7/5
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In order to estimate the current benzodiazepine doses of
the groups, all benzodiazepines were converted to
diazepam equivalent doses according to the Ashton table
[20]. In the cases of nitrazepam and temazepam the
diazepam equivalent doses were halved in order to
account for their use as hypnotics prior the night before
testing. After this conversion no statistically significant
difference existed between the patient groups in their
mean estimated diazepam equivalent dose, 23.0 mg (SD
= 20.2) in the methadone group and 19.6 mg (SD = 14.2)
in the buprenorphine/naloxone group.
Cognitive tests
A battery of cognitive tests included tests of attention,
working memory, and verbal memory.
Attention was assessed by the Alertness and Go/NoGo-
tasks from the Test for Attentional Performance (TAP)
which include computer software and RT key-pad. [21]. In
the Alertness task, visual RT was assessed with and with-
out preceding auditory warning signal. The without signal
condition of the Alertness test is a simple RT task, and is
thought to reflect tonic or intrinsic alertness [22]. The
with signal condition is thought to reflect both tonic and
phasic alertness. The conditions were presented in the A-
B-B-A – order. The Go/NoGo condition assessed integrity
of response-selection and executive control of attention
[23,24]. Visual stimuli were presented one by one. For two
stimuli out of five an instant reaction is required, and for
the others a reaction needs to be inhibited. Reaction times
and correctness of responses were recorded. In all the TAP
tests median of RTs was used as a RT parameter.
Working memory was assessed by the Letter-Number-
Sequencing task (LNS) from the Wechsler Memory Scale-
third version (WMS-III) and by the computerized version
of the Paced Auditory Serial Addition Task (PASAT) from
the FORAMENRehab software package [25-27]. The LNS
assesses verbal working memory storage added with
processing demand. In the PASAT complex working mem-
ory functions required are continuous storage of previous
number, rapid arithmetical processing, and executive con-
trol of interference from previous items or from ongoing
adding process. In our study presentation rate of a new
number to be added to the previous one was set as one in
every 1.6 second.
Verbal memory was assessed by a list learning task and by
a story recall task: the Memory for Persons Data (MPD)
and The Logical Memory (LM), respectively [25,28,29].
Both tests were presented in modified versions. In the LM,
which is a subtest of the WMS-III, only one story was pre-
sented and recalled immediately and again after 30 min-
utes. In the MPD only three persons, each with 5 items,
were presented. First there were two learning trials with
immediate recall. If the participant could recall all 15
items correctly in both trials no more learning trials were
administered. If this condition was not met, there were
additional trials until the participant was able to recall all
the items correctly in two consecutive trials. A maximum
of four trials were administered. After five minutes recall
of the items was asked for and possible errors were cor-
rected for. Finally, after 30 minutes delayed recall of all
the items was asked for.
Statistical analysis
Analysis of variance (ANOVA) was used to study the over-
all group effect in each cognitive test. This was followed,
when appropriate, by pair-wise group comparisons. We
used multiple planned ANOVAs because comparisons
were aimed at each variable separately. In all analyses, sta-
tistical significance was set at 0.05 (two-tailed). For each
variable we corrected multiple pair-wise comparisons by
Holm's procedure. We examined homogeneity of vari-
ances in each measure by Levene's test. In the simple RT
and the MPD first trial performance, the data was first
transformed by reciprocal or logarithmic transformation
to normalize the distributions. For the both of the Go/
NoGo conditions, the MPD last two last learning trials,
and in the MPD delayed recall the distributions could not
be normalized. First, we analyzed these results by non-
parametric Kruskal-Wallis ANOVA, which then were fol-
lowed, when appropriate, by pair-wise Mann-Whitney U
test. We did not covary for the group difference in educa-
tion favoring the control group over methadone group.
This was based on the contention that the assumption of
similar linear relation between education and cognitive
performance in both groups needed for analysis of covar-
iance (ANCOVA) was not met. All participants with opi-
oid dependence had started substance abuse in their early
teen years. Once the substance abuse history begins it
soon affects educational achievement by class non-attend-
ance etc. So, years of education does not reflect cognitive
ability in this populations similarly to the general popula-
tion [30]. However, in the second phase of the analysis, in
order to evaluate the role of premorbid intellectual fac-
tors, we set verbal IQ as a covariate for other measures
than RT measures. The association between simple RT
measures and intelligence is weak and may not be linear
[31]. Demographic data was studied as pair-wise group
comparisons without first requiring significant overall
group effect. Statistical analyses were done by SPSS statis-
tical software, version 13.0, with an exception of the effect
size calculations. For this purpose an effect size calculator
provided by Durham University, UK was employed [32].
In these analyses we used pooled samples and corrected
the values by Hedge's correction for small sample bias.BMC Clinical Pharmacology 2007, 7:5 http://www.biomedcentral.com/1472-6904/7/5
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Results
In the attention domain there were significant overall
group effects in two tasks: in the simple and Go/NoGo
RTs (F2,47 = 4.77, p = 0.013; χ2
2 = 6.39, p = 0.041, respec-
tively). In working memory, significant group effects were
found in both tasks employed; the LNS and the PASAT
(F2,46 = 11.99, p = 0.0001, F2,46 = 7.81, p = 0.001). In verbal
memory the group effect was significant in the verbal list
learning as measured by the MPD first trial and the MPD
delayed recall, and also in the immediate story recall as
measured by the LM (F 2,47 = 7.29, p = 0.002, χ2
2 = 9.24, p
= 0.01, F 2,47 = 5.49, p = 0.007). Table 3 shows group per-
formances in each cognitive test, along with statistical
analyses of pair-wise ANOVAs or Mann-Whitney U tests.
As seen in Table 3 buprenorphine/naloxone patients were
superior to methadone patients in the simple RT. The
buprenorphine/naloxone patients showed no difference
in attention tests compared to the control group. Rather
surprisingly, buprenorphine/naloxone patients were
slightly, but not statistically significantly, faster than con-
trols in simple RT. In this task their performance variance
was also reduced compared to other groups, which was
confirmed by Levene's test of equality of variances (F2,47 =
4.13, p = 0.022). Both methadone patients and controls
showed improvement of performance when RT was per-
formed after warning signal whereas buprenorphine/
naloxone patients showed no such improvement. In the
Go/NoGo RT, controls were superior to methadone
patients. In working memory tests controls were superior
to both groups of OST patients. In verbal memory con-
trols were superior to both patient groups in the MPD first
learning trial. In the immediate LM controls were superior
to methadone patients.
In order to investigate if group differences were due to dif-
ferences in premorbid intelligence between the groups,
the Verbal IQ estimate was set as a covariate for all tasks
with verbal stimuli. All statistically significant group dif-
ferences remained significant after adjusting for the cov-
ariate. Statistically significant group by Verbal IQ
interactions were not found.
Post hoc analyses were done in order to investigate the
role of benzodiazepine comedication on cognitive per-
formance between the OST drug groups. In these analyses
patients without current benzodiazepine medication were
Table 3: Groups comparisons of cognitive measures using ANOVA
Domain Test Methadone 
(n = 16)
Buprenorphine/
Naloxone
(n = 17)
Control
(n = 17)
Statistical comparisons 
between groups 
showing better 
performance first
Effect size 
(Cohen's d)
Mean ± SD Mean ± SD Mean ± SD
Attention
TAP Tonic Alertness, simple reaction time 257.6 ± 32.1 228.0 ± 13.0 244.4 ± 30.0 BN < M ** 1.11
TAP Phasic Alertness, reaction time after 
warning signal
245.6 ± 30.4 227.4 ± 17.0 230.3 ± 31.7
TAP Go/NoGo, reaction time 528.3 ± 82.0 496.9 ± 65.3a 465.5 ± 39.5 C < M* 0.88
TAP Go/NoGo, errors 0.6 ± 0.7 1.2 ± 1.4a 0.5 ± 0.6
Working memory
WMS-III LNS 8.8 ± 2.6b 8.7 ± 1.7 11.8 ± 3.1 C > M**
C > BN**
1.02
1.21
PASAT 34.9 ± 10.6b 31.3 ± 10.8 47.8 ± 9.3 C > M**
C > BN***
1.27
1.60
Memory
MPD, first trial 10.1 ± 3.0 10.6 ± 2.4 13.0 ± 1.4 C > M**
C > BN*
1.22
1.19
MPD, sum of two last trials 14.6 ± 1.0 14.8 ± 0.4 14.9 ± 0.2
MPD, delayed recall 13.9 ± 1.0 14.2 ± 1.0 14.8 ± 0.4 C > M**
C > BN*
WMS-III logical memory, immediate recall 12.5 ± 2.9 14.3 ± 3.6 16.3 ± 3.4 C > M** 1.17
WMS-III logical memory, delayed recall 11.1 ± 4.3 13.4 ± 3.3 14.5 ± 4.1
TAP = Test for Attentional Performance;
PASAT = Paced Auditory Serial Addition Task;
WMS-III = Wechsler Memory Scale-third version;
MPD = Memory for Persons Data.
C = control, M = methadone, BN = buprenorphine/naloxone
*** = statistically significant at level p < 0.001.
** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
an = 16.
bn = 15.BMC Clinical Pharmacology 2007, 7:5 http://www.biomedcentral.com/1472-6904/7/5
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excluded leaving 13 patients in both groups. After exclu-
sion all participants in both groups were dependent on
benzodiazepines and had used them within the last
month before the OST. The mean dose in the methadone
group was 54.2 mg (SD = 18.7) of methadone and 28.3
mg (SD = 18.6) of diazepam equivalent. The mean dose
in the buprenorphine/naloxone group was group was
16.3 mg (SD = 2.9) of buprenorphine and 25.6 mg (SD =
10.1) of diazepam equivalent. For demographic variables
there no significant differences emerged between groups.
The group with buprenorphine/naloxone and benzodi-
azepine medication was superior to the methadone group
with benzodiazepine medication in simple RT (U = 38.00,
p = 0.017) and in delayed recall of the LM (F1,24 = 6.15, p
= 0.021, d = 0.94)). Figure 1 depicts group performances
in both conditions of the LM.
Finally, post hoc analyses were made to study the role of
OST doses on cognitive performance. For these analyses
we split the patients groups into low and high dose groups
depending on their median OST drug dosage. After this
division the mean doses of methadone in the low dose (n
= 8) and high dose group (n = 8) were 40.0 mg (SD = 5.3)
and 66.9 mg (SD  = 17.3). Among buprenorphine/
naloxone patients nine patients received the same dose of
16 mg, and very few cases fell in the tails of the dose dis-
tribution. Therefore, dose analyses were restricted to
methadone patients. Patients with low a methadone dose
had faster RTs in all conditions than patients with high
dose. Figure 2 depicts these differences. In the simple RT
the difference reached statistical significance (p = 0.025, d
= 1.19). The mean simple RT time in the low methadone
dose group was 240.3 ms (SD = 29.9), which was very
close to the performance of the control group. No signifi-
cant differences between the groups were found in demo-
graphic variables except in days in the OST. The low dose
group had been fewer days on OST medication, mean 8.6
days, and high dose group, mean 20.0 days (SD = 1.9 vs.
6.3 respectively, p < 0.001). No significant differences
between the groups emerged in other psychoactive medi-
cations. In the low dose group 75% of the participants had
benzodiazepine and 25% had neuroleptic medication,
the corresponding figures being 88% and 25% in the high
dose group. In the low dose group 38% received hydrox-
yzine vs. 25% in the high dose group. Conversion of long
or intermediate acting benzodiazepines to a diazepam
equivalent dose neither showed significant difference
between the groups, mean dose for the low dose group
being 29.6 mg (SD = 28.7) and 18.1 in the high group (SD
= 10.9).
Discussion
In this first study comparing cognitive function of metha-
done- and buprenorphine/naloxone-treated patients dur-
ing early OST both patient groups were inferior to controls
in working memory and verbal memory. Methadone-
treated patients showed inferior performance also in
attention and more deficits in verbal memory. In the
attention task measuring alertness methadone-treated
patient were inferior to buprenorphine/naloxone-treated
patients. The effect sizes of group differences in compari-
son to controls in working memory and verbal memory
were close to the ones obtained in other studies of opioid-
dependent populations [33-35]. In attention tasks studies
with stabile OST patients the effect sizes have been varia-
ble depending on specific tasks used [36].
Working memory performance, which was inferior in
both patient groups, was measured by the PASAT and the
LNS tasks combining maintenance with organization of
material or with interference. Efficient performance of
these tasks depends on activation of widespread neural
networks including bilateral frontal and parietal cortices.
Especially pronounced activity is seen in right hemisphere
Comparison of high vs. low methadone dose groups in reac- tion times (RT) Figure 2
Comparison of high vs. low methadone dose groups in reac-
tion times (RT). * = p < 0.05
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[37,38]. Methadone-treatment of opioid-dependence
reduces cerebral blood flow (CBF) particularly in frontal
cortices and the patients often have left-greater-than-right
CBF asymmetry [39]. There are no similar studies con-
cerning buprenorphine treatment though buprenorphine
administration has been shown to reduce brain CBF in
substance abusing population [40]. In general, the CBF
reductions associated with opioid-dependence are proba-
bly linked to inadequate energy supply to the brain and
changes in releases of several neurotransmitters such as
catecholamines and acetylcholine [41,42]. Catecho-
lamines are important for integrity of working memory,
while acetylcholine is important also for learning and
memory consolidation. [43,44]. Thus, it does not aston-
ish that both OST groups showed inferior verbal list learn-
ing performance relative to controls. Methadone patients'
performance was reduced also in immediate story recall.
After excluding patients without benzodiazepine medica-
tion the difference between the methadone and buprenor-
phine group in delayed story recall appeared statistically
significant and showed a large effect size. Thus, it is possi-
ble that full mu opioid agonist methadone disrupts more
acetylcholine release and consequently impairs more ver-
bal memory than partial mu opioid agonist buprenor-
phine. Other factors that may be involved in memory
deficits of the OST patients are alterations of glutamater-
gic synapses after chronic opioid administration or inhibi-
tion of new cell formation in the hippocampus after
chronic mu opioid receptor activation [45,46].
Methadone patients were slower than buprenorphine/
naloxone patients in simple RT reflecting alertness and
slower than controls in the Go/NoGo RT task reflecting
response selection and executive control of attention. On
test day methadone patients received a mean dose of 23
mg diazepam equivalent medication and buprenorphine/
naloxone patients had been given 20 mg. It is known that
benzodiazepines such as diazepam or oxazepam, which
were commonly administered to the patients in this study
may have a slight negative effect on simple RT even
among long-term benzodiazepine users [47,48]. Thus,
benzodiazepine comedication may have affected the
results in RT tasks. It also possible that benzodiazepine
comedication would interact differently with methadone
than with buprenorphine/naloxone. This possibility is
supported by the results of a recent study by Lintzeris et al.
showing that mixing 10 or 20 mg of diazepam with a
mean 55 mg of methadone had significant detrimental
effect on simple RT and focused attention in methadone
patients [49]. Mixing the same amounts of diazepam with
mean 11 mg of buprenorphine had, however, minimal
effect on buprenorphine patients. In sum, we suggest that
methadone-treated patients with current benzodiazepine
medication tend to show inferior performance in atten-
tion tests relative to buprenorphine/naloxone-treated
patients with the same characteristics during early OST.
Consequently, it cannot be concluded that methadone, as
an OST monotherapy, would have different effect on atten-
tion performance than buprenorphine/naloxone mono-
therapy.
The good performance of buprenorphine/naloxone
patients in simple RT without warning signal along with
their reduced performance variance in this measure is a
surprising finding because buprenorphine has adverse
effect on RTs in healthy controls [9]. In some earlier stud-
ies methadone patients with stable doses also have out-
performed healthy controls in simple RT [11,50]. In one
study, a relatively low dose of methadone of, 33 mg or 16
mg, given during early inpatient opioid withdrawal treat-
ment actually speeded RTs of opioid-dependent patients in
comparison to placebo condition [12]. In our study meth-
adone patients on 40 mg outperformed methadone
patients on 67 mg dose. Together these observations raise
the possibility that a low dose of full mu opioid agonist
methadone or normal dose of partial mu opioid agonist
buprenorphine may have a minimal effect on simple RTs
of opioid-dependent patients in OST with high tolerance
for these opioids – and also for benzodiazepine comedi-
cation.
Limitations
Cognitive differences between the patient groups may
partly relate to differences in their OST drug-tolerance.
The majority of the patients in both groups had abused
buprenorphine during the recent month. In spite of cross-
tolerance to opioids, it is possible that switching from
buprenorphine to methadone results in transient cogni-
tive deficits in methadone patients. Thus, the possibility
of opioid switching effect in methadone-treated patients
during early OST cannot be ruled out. In order to investi-
gate this issue we are currently working on a follow-up
study with same patients.
Several psychoactive medications were used nearly simi-
larly in both groups to treat psychiatric comorbidity dur-
ing the OST initiation. These drugs, such as short acting
non-benzodiazepine zopiclone, neuroleptics, anticonvul-
sant valproate, or antihistamine hydroxyzine may have
slight adverse cognitive effects [51-54]. The interactions of
OST medications and all these medications warrant for
further studies.
All our participants were free from current substance
abuse as confirmed by drug screens. Instead, during the
recent month preceding the OST patients had used several
psychoactive substances. There were no major differences
between the uses of these substances within the patient
groups. Thus, these substances such as cannabis mayBMC Clinical Pharmacology 2007, 7:5 http://www.biomedcentral.com/1472-6904/7/5
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explain the differences between the studied OST patient
groups only if they have long-term effects and they inter-
act differently with the OST drugs. Therefore, long-term
benzodiazepine use may explain part of the similarities
between the OST patient groups. Long-term benzodi-
azepine monotherapy has adverse affect on several cogni-
tive functions, which may last at least for six months [55].
Opioid-dependent patients may already differ from the
general population in premorbid cognitive functions. Yet,
when we controlled for premorbid verbal intelligence by
using Verbal IQ estimate as a covariate in ANCOVA proce-
dure, this did not affect the results. Actually, this proce-
dure may be too conservative. A recent study has shown
that current smoking (if more than 8 cigarettes per day)
affects Verbal IQ [56]. Nearly all of our patients were daily
smokers. Thus, verbal IQ differences in these patients may
not to be primarily premorbid.
Conclusion
Both methadone and buprenorphine/naloxone-treated
OST patients show deficits in working memory and verbal
list learning during the early phase of their treatment. Def-
icits in attention may be seen only in methadone-treated
patients and their impairments may be dose-dependent.
Verbal memory deficit may be more extensive in metha-
done- than in buprenorphine/naloxone-treated patients.
Thus, this study further shows that in clinical samples, in
which recent benzodiazepine use and benzodiazepine
comedication as well as other psychoactive medications
are common, methadone-treated patients have more cog-
nitive deficits than buprenorphine- or buprenorphine/
naloxone-treated patients. Buprenorphine/naloxone may
preserve cognitive function in early OST better than meth-
adone, at least when benzodiazepine comedication is
used. Longitudinal studies are warranted to investigate
whether this advantage is permanent or is restricted to
early OST
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